HIV-1 Gag and Pol peptide–Major Histocompatibility Complex on alpha-type-1 polarized dendritic cells (HIV-1 Gag/Pol pMHC on αDC1)

HIV-1 Gag and Pol peptide–Major Histocompatibility Complex (MHC) on alpha-type-1 polarized dendritic cells (αDC1) represents a specialized immunological platform used in therapeutic HIV vaccines. αDC1 cells are a distinct subset of dendritic cells matured with a specific cytokine cocktail (typically including IL-1β, TNF-α, IFN-α, IFN-γ, and poly-I:C) to produce high levels of IL-12p70, which is critical for driving Type-1 immune responses (Mailliard et al., 2004, Cancer Research). These cells are loaded with peptides derived from the Gag (structural) and Pol (enzymatic) proteins of HIV-1, which are then presented on the cell surface via MHC Class I and II molecules. The primary biological function of this complex is to prime and expand HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 helper cells (Macatangay et al., 2016, Journal of Infectious Diseases). In the context of HIV infection, this approach aims to overcome the immune exhaustion and poor antigen presentation characteristic of chronic disease, potentially leading to better control of viral replication. Clinical strategies involving these complexes focus on autologous cell transfer to enhance the patient's own cellular immunity against conserved viral targets (Gandhi et al., 2016, Journal of Infectious Diseases).

Other names

HIV-1 Gag/Pol pMHC complexesαDC1-presented HIV antigensAlpha-type-1 polarized dendritic cell HIV vaccine

Induction of HIV-specific cytotoxic T lymphocytes (CTLs) and Th1 cells through the presentation of Gag and Pol epitopes via MHC Class I and II molecules, supported by high levels of IL-12p70 secretion from αDC1s.